Boehringer Ingelheim Corporation to Present Highly Anticipated Data From Landmark Tiospir™ Trial, and Their Respiratory Pipeline Products in COPD, Asthma, IPF and Lung Cancer at ERS 2013

F

or media outside the UK, US and Canada

•Results of COPD Phase III landmark trial TIOSPIR™ comparing safety and efficacy of SPIRIVA® Respimat® versus SPIRIVA® HandiHaler®

•Phase III trial results on investigational compound olodaterol* Respimat® as once-daily maintenance bronchodilator monotherapy in COPD

Help employers find you! Check out all the jobs and post your resume.